Targeted Protein Degradation Market Size, Share, Growth Analysis, By Type (Degronimids, Immunomodulatory Drugs (IMIDS)), By Therapeutic Area (Inflammatory Disorders, Neurological Disorders), By Route of Administration, By End Use By Region - Industry Forecast 2025-2032

It is considered that the competition within the global Targeted Protein Degradation market will intensify during the forecast period. This can be attributed to the entry of new players into the market and the increasing number of developments that are compatible with Targeted Protein Degradation. Presently, only a few major players are operating within the global market. However, this scenario is expected to change in the forthcoming years as more companies are likely to enter the market and offer their services.As the potential of Targeted Protein Degradation for the development of effective therapies for various diseases is becoming increasingly evident, there is a growing interest in this field. This has led to the entry of new players into the market, ranging from small startups to large pharmaceutical companies. With the increasing investments being made in research and development activities, more companies are expected to enter the market and offer their services, resulting in an intensified competitive landscape. Moreover, the growing number of developments compatible with Targeted Protein Degradation is expected to further increase the competition in the market. As more discoveries are made regarding the efficacy of this approach, it is expected to attract more companies, researchers, and investors to this field, thereby increasing the competition.

Targeted Protein Degradation Market Top Player’s Company Profiles

• Arvinas (USA) 
• Kymera Therapeutics (USA) 
• Nurix Therapeutics (USA) 
• C4 Therapeutics (USA) 
• Foghorn Therapeutics (USA) 
• Zymeworks (Canada) 
• Bristol-Myers Squibb (USA) 
• Pfizer (USA) 
• AbbVie (USA) 
• Sanofi (France) 
• Roche (Switzerland) 
• AstraZeneca (UK) 
• Vertex Pharmaceuticals (USA) 
• Amgen (USA) 
• Takeda Pharmaceutical (Japan) 
• Novartis (Switzerland) 
• Gilead Sciences (USA) 
• Merck & Co. (USA) 
• Janssen Pharmaceuticals (Johnson & Johnson) (USA) 
• BeiGene (China) 

Targeted Protein Degradation Market Recent Developments

• In January 2022, Salarius Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing novel treatments for sarcomas, pediatric cancers, and other cancers, entered into a definitive agreement with DeuteRx. As per the agreement, Salarius will acquire an oral, small molecule portfolio for targeted protein degradation, including a lead drug candidate previously known as DRX-164, which Salarius has renamed as SP-3164. The acquisition also includes the related patent family, which includes issued composition of matter patents, as well as the opportunity to develop additional cancer-fighting assets in the targeted protein degradation space.